The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis
Open Access
- 29 August 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Angiogenesis
- Vol. 13 (3), 259-267
- https://doi.org/10.1007/s10456-010-9183-z
Abstract
EphB4 and its cognitive ligand ephrinB2 play an important role in embryonic vessel development and vascular remodeling. In addition, several reports suggest that this receptor ligand pair is also involved in pathologic vessel formation in adults including tumor angiogenesis. Eph/ephrin signaling is a complex phenomena characterized by receptor forward signaling through the tyrosine kinase of the receptor and ephrin reverse signaling through various protein–protein interaction domains and phosphorylation motifs of the ephrin ligands. Therefore, interfering with EphR/ephrin signaling by the means of targeted gene ablation, soluble receptors, dominant negative mutants or antisense molecules often does not allow to discriminate between inhibition of Eph/ephrin forward and reverse signaling. We developed a specific small molecular weight kinase inhibitor of the EphB4 kinase, NVP-BHG712, which inhibits EphB4 kinase activity in the low nanomolar range in cellular assays showed high selectivity for targeting the EphB4 kinase when profiled against other kinases in biochemical as well as in cell based assays. Furthermore, NVP-BHG712 shows excellent pharmacokinetic properties and potently inhibits EphB4 autophosphorylation in tissues after oral administration. In vivo, NVP-BHG712 inhibits VEGF driven vessel formation, while it has only little effects on VEGF receptor (VEGFR) activity in vitro or in cellular assays. The data shown here suggest a close cross talk between the VEGFR and EphR signaling during vessel formation. In addition to its established function in vascular remodeling and endothelial arterio-venous differentiation, EphB4 forward signaling appears to be an important mediator of VEGF induced angiogenesis since inhibition of EphB4 forward signaling is sufficient to inhibit VEGF induced angiogenesis.Keywords
This publication has 46 references indexed in Scilit:
- Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesisNature, 2010
- Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesisNature, 2010
- Novel EphB4 Monoclonal Antibodies Modulate Angiogenesis and Inhibit Tumor GrowthThe American Journal of Pathology, 2010
- The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal TumorigenesisCancer Research, 2009
- Capillary Defects and Exaggerated Inflammatory Response in the Airways of EphA2-Deficient MiceThe American Journal of Pathology, 2009
- Eph-Ephrin Bidirectional Signaling in Physiology and DiseaseCell, 2008
- Paradoxes of the EphB4 Receptor in CancerCancer Research, 2007
- Receptor Tyrosine Kinase EphB4 Is a Survival Factor in Breast CancerThe American Journal of Pathology, 2006
- Inhibition of retinal neovascularization by soluble EphA2 receptorExperimental Eye Research, 2006
- Structure and Thermodynamic Characterization of the EphB4/Ephrin-B2 Antagonist Peptide Complex Reveals the Determinants for Receptor SpecificityStructure, 2006